Mayor Sylvester Turner says this new smart city technology partner will help digitize and optimize waste operations. Photo via rubicon.com

The City of Houston announced that it has entered into a three-year partnership with Kentucky-based Rubicon with the goal of improving its waste, recycling, and heavy-duty municipal fleet operations.

According to a statement, the city has installed the company's RUBICONSmartCity platform on the Solid Waste Management Department’s 391 vehicles, and has trained the workforce on using the SaaS software.

“Partnering with Rubicon will help our great city optimize its solid waste operations and make it possible for us to digitize our entire waste and recycling management system,” Mayor Sylvester Turner said in a statement. “The City of Houston is committed to providing the highest level of service to its residents and this partnership will allow us to provide better services, save taxpayer dollars, and deliver a better quality of life for Houstonians.”

RUBICONSmartCity is a cloud-based suite that will allow the department's workforce to track key metrics about pickup, including issues at the curb and recycling contamination, as well as information about its fleet of vehicles. The platform includes a mobile app, an onboard data collection device, and a web-based portal.

The city envisions that information collected by RUBICONSmartCity will enhance reporting tools used by 311 and give the department a better understanding of what's happening in the field.

“The City’s Department of Solid Waste can use this information to advise and educate residents around service scheduling, best practices for waste and recycling management, and reduce costly return trips,” Solid Waste Management Department Director Mark Wilfalk said in a statement. “These insights, alongside route optimization and digitization efforts, are set to deliver an optimal operation to the City of Houston.”

RUBICONSmartCity is used in more than 70 cities across the U.S., including San Antonio. The product was the focus of a 2021 Amazon documentary entitled "The Road to Zero Waste," which focused on Rubicon's work in Santa Fe, New Mexico.

“Our partnership with the City of Houston is off to a fantastic start, as we were able to install our products and train the entire Solid Waste Department’s workforce in only 73 days, an incredibly fast turn for such an undertaking,” Michael Allegretti, Chief Strategy Officer at Rubicon, said in a statement. "This partnership comes at a critically important time, as Houston and other cities across the nation look to maintain, and ultimately expand, service levels.”

In August 2021, the City of Houston also launched HTX Collects, a mobile app aimed at helping residents keep track of weekly services, updates, and waste collection days. At that time, the city estimated that it collected curbside service for over 395,000 residential homes within the city limits.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”